Sanofi has announced positive phase 3 data showing that nearly three times as many Dupixent patients experienced lower rates of itching and skin lesions at 24 weeks compared to the placebo.
Detailed positive results from the phase 3 prime trial evaluating Dupixent – also known as dupilumab – in adults with uncontrolled prurigo nodularis were presented at a session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress.
In total, 22 scientific abstracts are being presented at the EADV 2022 Congress discussing Dupixent in atopic dermatitis in patients as young as six months – and its investigational use in chronic spontaneous urticaria and bullous pemphigoid – in addition to prurigo nodularis.
